Citigroup’s Kalaris Therapeutics, Inc. Common Stock KLRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7
| Closed | -$66 | – | 5079 |
|
|
2024
Q4 | $66 | Sell |
7
-36
| -84% | -$339 | ﹤0.01% | 4835 |
|
|
2024
Q3 | $800 | Sell |
43
-289
| -87% | -$5.38K | ﹤0.01% | 4632 |
|
|
2024
Q2 | $5.53K | Sell |
332
-122
| -27% | -$2.03K | ﹤0.01% | 4492 |
|
|
2024
Q1 | $7.89K | Buy |
454
+129
| +40% | +$2.24K | ﹤0.01% | 4485 |
|
|
2023
Q4 | $5.08K | Buy |
325
+259
| +392% | +$4.05K | ﹤0.01% | 4557 |
|
|
2023
Q3 | $3.28K | Sell |
66
-608
| -90% | -$30.2K | ﹤0.01% | 4090 |
|
|
2023
Q2 | $52.7K | Buy |
674
+563
| +507% | +$44K | ﹤0.01% | 3940 |
|
|
2023
Q1 | $10.1K | Sell |
111
-2
| -2% | -$181 | ﹤0.01% | 4063 |
|
|
2022
Q4 | $13.3K | Buy |
113
+1
| +0.9% | +$118 | ﹤0.01% | 4037 |
|
|
2022
Q3 | $20K | Sell |
112
-167
| -60% | -$29.8K | ﹤0.01% | 4034 |
|
|
2022
Q2 | $25K | Buy |
279
+17
| +6% | +$1.52K | ﹤0.01% | 4187 |
|
|
2022
Q1 | $41K | Sell |
262
-2,234
| -90% | -$350K | ﹤0.01% | 4108 |
|
|
2021
Q4 | $743K | Buy |
2,496
+1,100
| +79% | +$327K | ﹤0.01% | 2801 |
|
|
2021
Q3 | $804K | Sell |
1,396
-3,497
| -71% | -$2.01M | ﹤0.01% | 2551 |
|
|
2021
Q2 | $2.22M | Buy |
4,893
+816
| +20% | +$370K | ﹤0.01% | 2028 |
|
|
2021
Q1 | $2.19M | Buy |
4,077
+3,812
| +1,438% | +$2.05M | ﹤0.01% | 1877 |
|
|
2020
Q4 | $234K | Buy |
265
+228
| +616% | +$201K | ﹤0.01% | 3149 |
|
|
2020
Q3 | $24K | Buy |
+37
| New | +$24K | ﹤0.01% | 3852 |
|